Literature DB >> 7644764

Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis.

F Keller1, H Heinze, F Jochimsen, J Passfall, D Schuppan, P Büttner.   

Abstract

The prognosis of acute renal failure in patients with preexisting liver decompensation is poor, and hemodialysis is considered futile, especially for hepatorenal syndrome (HRS). Since we observed a more favorable outcome in some patients, we retrospectively evaluated 107 patients with decompensated liver disease and acute renal failure (serum creatinine > 200 mumol/L) treated at the medical department of a university hospital in a 10-year period (1980-1990). HRS in the strict sense (urine-Na < 20 mmol/L while on furosemide) was diagnosed in 26 of 107 patients (24%). Renal function remained compensated in 25 patients, while 82 patients fulfilled the criteria for dialysis treatment (creatinine > 500 mumol/L and/or diuresis < 500 mL/day). In contrast to the current doctrine, 38 of the 82 patients were given hemodialysis (46%). Using the Cox proportional hazard model, the relative risk (presence vs. absence of a risk factor) of dying was increased 8.2-fold (3.9-17.2) in patients with thrombocytopenia < 100/nL, 3.9-fold (1.4-11.3) in those with hepatic encephalopathy and prothrombin time < 30%, 2.8-fold (1.6-4.8) in patients with malignoma, and 2.7-fold (1.5-4.8) in patients not submitted to dialysis despite its indication. In the CART statistics (classification and regression trees), the 33 patients with the poorest outcome were characterized exclusively by thrombocytopenia < 100/nL. HRS in the strict sense was not an independent risk factor. The CART group of 43 patients with favorable prognosis (compensated renal failure or treatment by hemodialysis, absent malignancy) had a 1-year survival rate of 38%. We conclude that thrombocytopenia, encephalopathy, and malignoma, but not HRS per se, are fatal signs that make hemodialysis futile in patients with acute renal failure and decompensated liver disease.

Entities:  

Mesh:

Year:  1995        PMID: 7644764     DOI: 10.3109/08860229509026250

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  23 in total

1.  [6 years of the International Union of Societies of Immunology. Presidential report (Brighton 1974)].

Authors:  B Cinader
Journal:  Medicina (B Aires)       Date:  1975 Jul-Aug       Impact factor: 0.653

Review 2.  Improvement in central nervous system functions during treatment of liver failure with albumin dialysis MARS--a review of clinical, biochemical, and electrophysiological data.

Authors:  S Mitzner; J Loock; P Peszynski; S Klammt; J Majcher-Peszynska; A Gramowski; J Stange; R Schmidt
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

Review 3.  Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options.

Authors:  Brian Erly; William D Carey; Baljendra Kapoor; J Mark McKinney; Mathew Tam; Weiping Wang
Journal:  Semin Intervent Radiol       Date:  2015-12       Impact factor: 1.513

Review 4.  Hepatorenal syndrome: Update on diagnosis and treatment.

Authors:  Olga Baraldi; Chiara Valentini; Gabriele Donati; Giorgia Comai; Vania Cuna; Irene Capelli; Maria Laura Angelini; Maria Ilaria Moretti; Andrea Angeletti; Fabio Piscaglia; Gaetano La Manna
Journal:  World J Nephrol       Date:  2015-11-06

Review 5.  Hepatorenal syndrome.

Authors:  Sharon Turban; Paul J Thuluvath; Mohamed G Atta
Journal:  World J Gastroenterol       Date:  2007-08-14       Impact factor: 5.742

6.  Prognosis of Patients with Cirrhosis and AKI Who Initiate RRT.

Authors:  Andrew S Allegretti; Xavier Vela Parada; Nwamaka D Eneanya; Hannah Gilligan; Dihua Xu; Sophia Zhao; Jules L Dienstag; Raymond T Chung; Ravi I Thadhani
Journal:  Clin J Am Soc Nephrol       Date:  2017-11-09       Impact factor: 8.237

Review 7.  Management of hepatorenal syndrome.

Authors:  Halit Ziya Dundar; Tuncay Yılmazlar
Journal:  World J Nephrol       Date:  2015-05-06

Review 8.  Management of hepatorenal syndrome in patients with cirrhosis.

Authors:  Vicente Arroyo; Javier Fernández
Journal:  Nat Rev Nephrol       Date:  2011-08-09       Impact factor: 28.314

Review 9.  Renal dysfunction in cirrhosis.

Authors:  Nathalie H Urrunaga; Ayse L Mindikoglu; Don C Rockey
Journal:  Curr Opin Gastroenterol       Date:  2015-05       Impact factor: 3.287

10.  Therapeutic alternatives for the treatment of type 1 hepatorenal syndrome: A Delphi technique-based consensus.

Authors:  Juan P Arab; Juan C Claro; Juan P Arancibia; Jorge Contreras; Fernando Gómez; Cristian Muñoz; Leyla Nazal; Eric Roessler; Rodrigo Wolff; Marco Arrese; Carlos Benítez
Journal:  World J Hepatol       Date:  2016-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.